What does the largest cohort study of AF patients with stable coronary artery disease suggest about the use of VKA plus aspirin or clopidogrel relative to VKA monotherapy?
The largest cohort study of AF patients with stable coronary artery disease, reported by Lamberts et al293, found that the risk of MI/coronary death was similar for VKA plus aspirin (HR, 1.12; 95% CI, 0.94-1.34) and VKA plus clopidogrel (HR, 1.53; 95% CI, 0.93-2.52) relative to VKA monotherapy. However, the risk of bleeding increased by more than 50% when aspirin (HR, 1.50; 95% CI, 1.23-1.82) or clopidogrel (HR, 1.84; 95% CI, 1.11-3.06) was added to VKA.